The independent source for health policy research, polling, and news.
641-660 of 704 results
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.
Despite heavy opposition from the pharmaceutical industry and skepticism from policy experts, many voters see Proposition 61 as a way to protest the nation’s mounting drug prices.
Majorities of Democrats, Republicans and independents support making sure high-cost drugs for chronic conditions are affordable.
Climbing drug prices are taking a toll on West Virginia's budget, some state legislators say. Expensive drugs fuel an increase in Medicaid spending, which leaves less money for schools and roads.
The plans sought to discourage costly HIV patients by not including their drug needs in formularies or requiring high cost sharing, a Harvard Law School group says in a complaint filed with HHS.
In a report out Tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
KHN’s Julie Appleby joined forces with USA Today to create this chart, which details the various industry players and how they contribute to a prescription drug’s cost.
Ten-year-old Josh Hardy died last month. His struggle to survive helped to spur laws to get unapproved drugs to the terminally ill.
A voucher awarded to companies that find treatments for rare childhood diseases can be sold to the highest bidder — and then used to speed up approvals for much more common drugs.
Such medications account for more than a quarter of the state agency’s $2.1 billion in pharmacy costs.
The number of prescriptions for Medicare beneficiaries is on the rise, too.
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
The legislation would have required drug companies to notify the state and insurers about expensive new treatments or price hikes.
© 2026 KFF